NM_000535.7(PMS2):c.652G>A (p.Gly218Ser) AND Hereditary cancer-predisposing syndrome

Clinical significance:Conflicting interpretations of pathogenicity, Likely benign(1);Uncertain significance(1) (Last evaluated: Sep 8, 2020)

Review status:1 star out of maximum of 4 stars

criteria provided, conflicting interpretations

Based on:
2 submissions [Details]
Record status:

Allele description [Variation Report for NM_000535.7(PMS2):c.652G>A (p.Gly218Ser)]

NM_000535.7(PMS2):c.652G>A (p.Gly218Ser)

PMS2:PMS1 homolog 2, mismatch repair system component [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_000535.7(PMS2):c.652G>A (p.Gly218Ser)
  • NC_000007.14:g.5999161C>T
  • NG_008466.1:g.14946G>A
  • NM_000535.7:c.652G>AMANE SELECT
  • NM_001322003.2:c.247G>A
  • NM_001322004.2:c.247G>A
  • NM_001322005.2:c.247G>A
  • NM_001322006.2:c.652G>A
  • NM_001322007.2:c.334G>A
  • NM_001322008.2:c.334G>A
  • NM_001322009.2:c.247G>A
  • NM_001322010.2:c.247G>A
  • NM_001322011.2:c.-282G>A
  • NM_001322012.2:c.-282G>A
  • NM_001322013.2:c.133-1738G>A
  • NM_001322014.2:c.652G>A
  • NM_001322015.2:c.343G>A
  • NP_000526.2:p.Gly218Ser
  • NP_001308932.1:p.Gly83Ser
  • NP_001308933.1:p.Gly83Ser
  • NP_001308934.1:p.Gly83Ser
  • NP_001308935.1:p.Gly218Ser
  • NP_001308936.1:p.Gly112Ser
  • NP_001308937.1:p.Gly112Ser
  • NP_001308938.1:p.Gly83Ser
  • NP_001308939.1:p.Gly83Ser
  • NP_001308943.1:p.Gly218Ser
  • NP_001308944.1:p.Gly115Ser
  • LRG_161t1:c.652G>A
  • LRG_161:g.14946G>A
  • NC_000007.13:g.6038792C>T
  • NM_000535.5:c.652G>A
  • NM_000535.6:c.652G>A
  • NR_136154.1:n.739G>A
Protein change:
dbSNP: rs878854055
NCBI 1000 Genomes Browser:
Molecular consequence:
  • NM_001322011.2:c.-282G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322012.2:c.-282G>A - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001322013.2:c.133-1738G>A - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000535.7:c.652G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322003.2:c.247G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322004.2:c.247G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322005.2:c.247G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322006.2:c.652G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322007.2:c.334G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322008.2:c.334G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322009.2:c.247G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322010.2:c.247G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322014.2:c.652G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001322015.2:c.343G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_136154.1:n.739G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]


Hereditary cancer-predisposing syndrome
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
MONDO: MONDO:0015356; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV001187553Ambry Geneticscriteria provided, single submitter
Likely benign
(Apr 4, 2019)
germlineclinical testing

Citation Link,

SCV001341887Color Health, Inccriteria provided, single submitter
Uncertain significance
(Sep 8, 2020)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot provided1not providedclinical testing



Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]

Details of each submission

From Ambry Genetics, SCV001187553.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided


In silico models in agreement (benign);Other strong data supporting benign classification

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknown1not providednot provided1not providednot providednot provided

From Color Health, Inc, SCV001341887.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This missense variant replaces glycine with serine at codon 218 of the PMS2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 12, 2021

Support Center